AnaptysBio Inc (ANAB) - Total Liabilities
Based on the latest financial reports, AnaptysBio Inc (ANAB) has total liabilities worth $316.94 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
AnaptysBio Inc - Total Liabilities Trend (2013–2025)
This chart illustrates how AnaptysBio Inc's total liabilities have evolved over time, based on quarterly financial data. See AnaptysBio Inc short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
AnaptysBio Inc Competitors by Total Liabilities
The table below lists competitors of AnaptysBio Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Swan Energy Limited
NSE:SWANENERGY
|
India | Rs61.97 Billion |
|
Bio-Rad Laboratories Inc
NYSE:BIO-B
|
USA | $3.09 Billion |
|
Serena Energia S.A.
SA:SRNA3
|
Brazil | R$15.23 Billion |
|
Turning Point Brands Inc
NYSE:TPB
|
USA | $386.61 Million |
|
Metrovacesa SA
MC:MVC
|
Spain | €843.82 Million |
|
Fila Holdings Corp
KO:081660
|
Korea | ₩2.75 Trillion |
|
Ingersoll Rand (India) Limited
NSE:INGERRAND
|
India | Rs3.34 Billion |
|
Shenzhen Gongjin Electn
SHG:603118
|
China | CN¥5.30 Billion |
Liability Composition Analysis (2013–2025)
This chart breaks down AnaptysBio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is AnaptysBio Inc worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.58 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 24.86 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.96 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how AnaptysBio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for AnaptysBio Inc (2013–2025)
The table below shows the annual total liabilities of AnaptysBio Inc from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $327.19 Million | -20.77% |
| 2024-12-31 | $412.97 Million | +13.36% |
| 2023-12-31 | $364.29 Million | +4.60% |
| 2022-12-31 | $348.28 Million | +21.50% |
| 2021-12-31 | $286.64 Million | +1346.15% |
| 2020-12-31 | $19.82 Million | -34.34% |
| 2019-12-31 | $30.19 Million | +33.39% |
| 2018-12-31 | $22.63 Million | +3.90% |
| 2017-12-31 | $21.78 Million | -4.93% |
| 2016-12-31 | $22.91 Million | +64.33% |
| 2015-12-31 | $13.94 Million | -26.89% |
| 2014-12-31 | $19.07 Million | +406.02% |
| 2013-12-31 | $3.77 Million | -- |
About AnaptysBio Inc
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial… Read more